FDA approves sotatercept for pulmonary arterial hypertension
The FDA has approved sotatercept, an activin signaling inhibitor, for treating adults with pulmonary arterial hypertension, according to a manufacturer-issued press release.In September 2023, the FDA granted priority review to sotatercept (Winrevair, Merck).